Phase I/IIa trials of a novel T-cell epitope-based peptide therapy for peanut allergy

新型基于 T 细胞表位的肽疗法治疗花生过敏的 I/IIa 期试验

• 批准号: nhmrc : GNT1107228
• 负责人: Prof Robyn O'Hehir
• 金额: $ 144万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/phase-iiia-trials-peanut-allergy/1346569
• 关键词: Phase; IIa; trials; novel; cell

Peanut allergy affects ~2% of the population and is the major cause of food triggered deaths from anaphylaxis. Typically peanut allergy is lifelong. Currently there is no specific treatment. Our vast experience in immunology for house dust mite and grass immunotherapy allowed us to identify critical components of peanut proteins needed as a safe vaccine to build tolerance to peanut foods. Now we will progress this novel and revolutionary vaccine through early phase clinical trials.

花生过敏影响约2%的人口，是食物引发的过敏性死亡的主要原因。花生过敏通常是终生的。目前没有具体的治疗方法。我们在室内尘螨和草免疫治疗免疫学方面的丰富经验使我们能够确定花生蛋白的关键成分，作为建立对花生食物耐受性的安全疫苗。现在我们将通过早期临床试验来推进这种新型的革命性疫苗。